Citius Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.19 Insider Own8.79% Shs Outstand146.04M Perf Week2.16%
Market Cap132.07M Forward P/E8.75 EPS next Y0.10 Insider Trans0.00% Shs Float133.72M Perf Month-30.91%
Income-25.60M PEG- EPS next Q-0.07 Inst Own18.80% Short Float9.90% Perf Quarter-45.69%
Sales- P/S- EPS this Y49.60% Inst Trans-0.17% Short Ratio7.01 Perf Half Y-49.35%
Book/sh0.81 P/B1.11 EPS next Y-35.30% ROA- Target Price6.67 Perf Year-58.83%
Cash/sh0.38 P/C2.37 EPS next 5Y- ROE- 52W Range0.86 - 4.56 Perf YTD-41.45%
Dividend- P/FCF- EPS past 5Y37.10% ROI- 52W High-80.70% Beta1.65
Dividend %- Quick Ratio14.50 Sales past 5Y- Gross Margin- 52W Low2.35% ATR0.10
Employees15 Current Ratio14.50 Sales Q/Q- Oper. Margin- RSI (14)35.10 Volatility6.98% 9.92%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.76 Prev Close0.90
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.89M Price0.88
Recom2.00 SMA20-11.85% SMA50-36.60% SMA200-47.72% Volume176,856 Change-2.37%
Nov-30-21Initiated Maxim Group Buy $4
May-18-22 09:30AM  
May-12-22 04:30PM  
May-11-22 07:34AM  
May-10-22 11:10AM  
May-08-22 09:00AM  
May-06-22 09:37AM  
May-03-22 10:06AM  
Apr-26-22 08:30AM  
Apr-14-22 09:25AM  
Apr-13-22 09:25AM  
Apr-07-22 09:57AM  
Apr-06-22 08:14AM  
Mar-29-22 10:18AM  
Mar-03-22 09:15AM  
Mar-02-22 04:12AM  
Feb-15-22 09:15AM  
Feb-10-22 04:30PM  
Jan-04-22 09:00AM  
Dec-15-21 04:30PM  
Dec-06-21 09:15AM  
Dec-02-21 05:17AM  
Nov-05-21 09:15AM  
Oct-25-21 09:15AM  
Oct-13-21 11:38AM  
Oct-06-21 10:40AM  
Oct-04-21 12:31PM  
Oct-01-21 08:30AM  
Sep-23-21 12:12PM  
Sep-16-21 10:38AM  
Sep-14-21 10:06AM  
Sep-08-21 11:34AM  
Sep-07-21 07:30AM  
Aug-12-21 04:30PM  
Aug-04-21 10:34AM  
Aug-03-21 04:29PM  
Jul-20-21 07:17AM  
Jul-07-21 07:15PM  
Jul-01-21 12:56PM  
Jun-23-21 07:51AM  
Jun-21-21 06:50PM  
Jun-17-21 06:00AM  
Jun-16-21 05:55PM  
Jun-15-21 09:20AM  
Jun-08-21 02:11PM  
Jun-07-21 09:00AM  
Jun-03-21 08:18AM  
May-25-21 02:52PM  
May-18-21 09:29AM  
May-17-21 12:30PM  
May-13-21 07:30AM  
May-11-21 04:30PM  
May-04-21 09:15AM  
Apr-29-21 09:37AM  
Apr-22-21 04:30PM  
Apr-19-21 08:53AM  
Mar-23-21 09:00AM  
Mar-04-21 10:11AM  
Feb-19-21 04:47PM  
Feb-17-21 12:28AM  
Feb-16-21 09:15AM  
Feb-08-21 08:35AM  
Feb-04-21 10:16AM  
Feb-02-21 08:00AM  
Jan-28-21 08:35AM  
Jan-27-21 01:00PM  
Jan-25-21 07:00AM  
Jan-06-21 09:00AM  
Dec-18-20 12:57AM  
Dec-15-20 09:40AM  
Dec-09-20 09:40AM  
Dec-08-20 09:15AM  
Dec-03-20 03:30PM  
Nov-30-20 09:15AM  
Nov-10-20 09:30AM  
Nov-09-20 09:30AM  
Oct-27-20 09:00AM  
Oct-13-20 07:30AM  
Oct-07-20 07:00AM  
Sep-30-20 09:45AM  
Sep-29-20 10:17AM  
Sep-22-20 08:15AM  
Sep-15-20 10:17AM  
Sep-08-20 10:00AM  
Sep-01-20 04:34PM  
Aug-27-20 09:00AM  
Aug-26-20 10:00AM  
Aug-13-20 09:45AM  
Aug-10-20 03:18PM  
Aug-05-20 05:32PM  
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.